Objectives: Asthma is one of the most common chronic diseases worldwide and can often be controlled by treatments. However, in 5-10% of patients have severe asthma. Anti-IgE (Omalizumab) is indicated for asthma patients who have an allergic-sensitivity with a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids. There are papers that patients with severe asthma are non-adherent to treatment or that their compliance to preventer inhaler treatments after omalizumab treatment is impaired. We aimed to evaluate the adherence with preventer inhaler therapy in severe asthmatic patients receiving omalizumab.
